Climb Bio (CLYM) Non-Current Deferred Tax Liability (2021 - 2025)
Climb Bio's (CLYM) quarterly Non-Current Deferred Tax Liability came in at $91000.0 in Q4 2025, down 34.06% YoY from $138000.0 in Q4 2024, and down 34.06% on a QoQ basis from $138000.0 in Q4 2024.
Analysis
Climb Bio (CLYM) Non-Current Deferred Tax Liability (2021 - 2025) Analysis & Trends
Climb Bio (CLYM) has 3 years of Non-Current Deferred Tax Liability data on file, last reported at $91000.0 in Q4 2025.
- Quarterly Non-Current Deferred Tax Liability fell 34.06% year-over-year to $91000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $91000.0 (down 34.06% YoY) and the FY2025 annual result came in at $91000.0, down 34.06% from the prior year.
- Non-Current Deferred Tax Liability retreated to $91000.0 in Q4 2025, from $138000.0 in the prior quarter.
- In the past five years, Non-Current Deferred Tax Liability ranged from a high of $138000.0 in Q4 2024 to a low of -$11000.0 in Q4 2021.
- A 3-year average of $72666.7 and a median of $91000.0 in 2025 frame the typical range for Non-Current Deferred Tax Liability.
- The widest YoY moves for Non-Current Deferred Tax Liability: up 34.06% in 2025, down 34.06% in 2025.
- Tracing CLYM's Non-Current Deferred Tax Liability over 3 years: stood at -$11000.0 in 2021, then jumped by 1354.55% to $138000.0 in 2024, then tumbled by 34.06% to $91000.0 in 2025.
- The last three Non-Current Deferred Tax Liability figures came in at $91000.0 (Q4 2025), $138000.0 (Q4 2024), and -$11000.0 (Q4 2021), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Climb Bio | 1.18 Bn | 1.18 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 91,000.00 |
| Dec 31, 2024 | 138,000.00 |
| Dec 31, 2021 | -11,000.00 |